Osiris Therapeutics, Inc. (OSIR) Reports First Quarter 2014 Results: Revenue Up 25% And Gross Margin Improved From 73% To 78%
5/13/2014 7:04:32 AM
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets announced today its financial results for the first quarter of 2014.
Highlights and Recent Developments
•Increased product revenue for the quarter to $10.1 million - a 146% increase over the first quarter of 2013 and 25% from previous quarter.
Help employers find you! Check out all the jobs and post your resume.
comments powered by